The vaccine hasn’t completed phase 3 trials, so we can’t be sure it will be safe and effective for all. The Australian government’s deal is contingent on these trials being successful.
Academic rigor, journalistic flair
Articles on COVID-19 vaccines
Displaying 561 - 576 of 576 articles
As Russia fast tracks a coronavirus vaccine, scientists worry about skipped safety checks – and the potential fallout for trust in vaccines if something ends up going wrong.
Most people will know someone who has succumbed to conspiracy theories about coronavirus – here’s how to talk to them.
The race is on to develop a vaccine for the COVID-19 coronavirus. Australian researchers are leading several major clinical trials that might help bring an end to the deadly disease.
The results from the phase 1 trial are a promising first step in showing that the mRNA vaccine is a viable candidate, but there are unanswered questions and it is still early in the process.
The high cost of pharmaceuticals often means only the richest patients get lifesaving medicines. As coronavirus drugs emerge, it will require hard, creative work to ensure they’re available to all.
Nanoparticles dressed up in cell membranes snag SARS-CoV-2 virus particles before they reach human cells.
CC BY-NC-ND9.01 MB (download)
South Africa is trialling a vaccine for COVID-19. Here's what you need to know about it.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
A lot depends on China and India sharing the products of their pharmacuetical manufacturing with the rest of the world.
The UK is investing heavily in preparation for mass manufacturing of a working COVID-19 vaccine.
South Africa’s response to the COVID-19 pandemic was one of ‘intervene first and ask questions later’. Now is the time for government to state clearly what its strategic endgame is.
As most of the world early awaits a vaccine for COVID-19, a smaller group of people scoffs. They could spell real trouble in the effort to build widespread immunity.
Drug repurposing represents our only hope for the treatment of COVID-19 in the short term. But quick and rigorous trials need to be run to provide evidence these drugs work.
Coronavirus drug trials are underway – a virologist explains what the treatment options may be.
The SARS-CoV-2 virus that causes COVID-19 is constantly mutating. What do these mutations reveal about this virus’s evolution? And will this knowledge help us to develop a long-lasting vaccine?
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
